Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 3Gynecologic 2Thoracic 1Other hematologic neoplasm 1NET 1Lymphoid 1Endocrine 1Breast 1

Conditions

Neuroendocrine Tumors 169Carcinoma, Neuroendocrine 73Thyroid Neoplasms 52Pheochromocytoma 45Thyroid Carcinoma, Anaplastic 42Thyroid Cancer, Papillary 42Adrenocortical Carcinoma 40Carcinoid Tumor 39Paraganglioma 35Adenocarcinoma, Follicular 33Neoplasm Metastasis 29Neoplasms 28Somatostatinoma 26Adenoma, Islet Cell 26Insulinoma 22Carcinoma, Medullary 22Carcinoma, Islet Cell 22Pancreatic Neoplasms 21Pituitary Neoplasms 20Sarcoma 19Glucagonoma 19Gastrinoma 19Gastro-enteropancreatic neuroendocrine tumor 16Head and Neck Neoplasms 15Colorectal Neoplasms 14Multiple Endocrine Neoplasia Type 1 13Neuroblastoma 12Carcinoma, Renal Cell 12Carcinoma, Non-Small-Cell Lung 12Vipoma 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hypersensitivity × Endocrine × Clear all
NCT01673906 2025-06-24

68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours

Azienda USL Reggio Emilia - IRCCS

Phase 2 Completed
142 enrolled
EndocrineNET

Hypersensitivity, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡